Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 3,303 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Circulatory System Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Caffeine on Heart Function

NCT02401776
View directory record Official record
Conditions
Fatigue, Tachycardia
Interventions
Monster Energy Drink, Coffee
Dietary Supplement
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 35 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 14, 2026, 10:20 PM EDT
Terminated Phase 1 Interventional

Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies

NCT00526838
View directory record Official record
Conditions
Cancer, Lymphoma
Interventions
XL228
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Los Angeles, California • Atlanta, Georgia • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 14, 2026, 10:20 PM EDT
Completed Not applicable Interventional

Electronic Alerts for Stroke Prevention in Atrial Fibrillation

NCT02958943
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
On-screen electronic alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 14, 2026, 10:20 PM EDT
Completed Not applicable Interventional

Prebiotics, Gut Microbiota, and Cardiometabolic Health

NCT02346838
View directory record Official record
Conditions
Prediabetes
Interventions
Inulin, Placebo
Dietary Supplement
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
40 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 14, 2026, 10:20 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

New Heart Imaging Techniques to Evaluate Possible Heart Disease

NCT01399385
View directory record Official record
Conditions
Healthy, Obesity, Diabetes, Healthy Volunteers, Atherosclerosis
Interventions
MR Imaging Techniques - 1, MR Imaging Techniques - 2, MR Imaging Techniques - 3, MR Imaging Techniques - 4
Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 10:20 PM EDT
Withdrawn Phase 2 Interventional

A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma

NCT02402725
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 14, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

NCT02795676
View directory record Official record
Conditions
Fabry Disease
Interventions
PRX-102 (pegunigalsidase alfa), agalsidase beta
Biological
Lead sponsor
Protalix
Industry
Eligibility
18 Years to 60 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 14, 2026, 10:20 PM EDT
Withdrawn Not applicable Interventional

Early Feasibility Study of the Nervive VitalFlow Stimulation for Acute Ischemic Stroke Patients

NCT04801225
View directory record Official record
Conditions
Acute Stroke
Interventions
Non-invasive electromagnetic stimulation for acute stroke treatment
Device
Lead sponsor
Nervive, Inc.
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 14, 2026, 10:20 PM EDT
Active, not recruiting Phase 4 Interventional

US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair

NCT04852783
View directory record Official record
Conditions
Aneurysm, Intracranial
Interventions
Contour Neurovascular System
Device
Lead sponsor
Cerus Endovascular, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
20
States / cities
Englewood, Colorado • Jacksonville, Florida • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 14, 2026, 10:20 PM EDT
Active, not recruiting Not applicable Interventional

Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular Access

NCT06712251
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Hemodialysis, End Stage Renal Disease (ESRD)
Interventions
Velocity pAVF System
Device
Lead sponsor
Venova Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Dothan, Alabama • Riverside, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 14, 2026, 10:20 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

NCT04603937
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
40
States / cities
Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 14, 2026, 10:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers

NCT06403605
View directory record Official record
Conditions
Diabetic Foot Ulcer, Ulcer Foot, Diabetic Foot
Interventions
Mirragen Advanced Wound Matrix, Fibracol
Device
Lead sponsor
ETS Wound Care, LLC
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
15
States / cities
Los Angeles, California • Pomona, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 14, 2026, 10:20 PM EDT
Completed Phase 4 Interventional

Subcutaneous Amifostine Safety Study

NCT00158041
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer, Lymphoma
Interventions
Amifostine administered subcutaneously
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 12, 2005 · Synced Oct 14, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

NCT01458288
View directory record Official record
Conditions
Multiple Myeloma, Non-hodgkin's Lymphoma, Hodgkin's Disease
Interventions
TG-0054
Drug
Lead sponsor
GPCR Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 14, 2026, 10:20 PM EDT
Completed No phase listed Observational

Assessment of Patients With Multiple Sclerosis (MS)

NCT00001156
View directory record Official record
Conditions
Herpesviridae Infection, HTLV-I Infection, Multiple Sclerosis, Tropical Spastic Paraparesis, Vasculitis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1976 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 10:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Long Term Health Outcomes of Women Veterans' Service During the Vietnam Era

NCT00958061
View directory record Official record
Conditions
Post-Traumatic Stress Disorder, Depression, Diabetes, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Female only
Enrollment
4,219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Charleston, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 14, 2026, 10:20 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

NCT04764942
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Pomalidomide, Quality-of-Life Assessment, Questionnaire Administration, Selinexor, X-Ray Imaging, Computed Tomography, Positron Emission Tomography, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 14, 2026, 10:20 PM EDT
Completed Phase 4 Interventional Results available

Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus

NCT04484259
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Coronary Artery Disease
Interventions
Ticagrelor monotherapy, Ticagrelor plus aspirin, Clopidogrel with aspirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 14, 2026, 10:20 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)

NCT05865054
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Magnetic Resonance Imaging (MRI)
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2033
U.S. locations
2
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 10:20 PM EDT
Completed Not applicable Interventional Results available

A Prospective, Randomized, Double-Blind Multicenter Study Comparing CDO Therapy to Standard MWT in the Treatment of DFUs

NCT01645891
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
CDO electrochemical tissue oxygenation system, Moist Wound Therapy
Device
Lead sponsor
Electrochemical Oxygen Concepts, Inc.
Industry
Eligibility
30 Years to 90 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
33
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 14, 2026, 10:20 PM EDT
Completed Phase 2 Interventional

Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

NCT03482479
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis
Interventions
Naltrexone Hydrochloride, Placebo Comparator
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
6
States / cities
Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 14, 2026, 10:20 PM EDT
Completed Phase 3 Interventional

Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.

NCT00047580
View directory record Official record
Conditions
Multiple Sclerosis, Muscle Spasticity, Spinal Cord Injury, Stroke
Interventions
tizanidine hydrochloride capsule
Drug
Lead sponsor
Elan Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
16
States / cities
Tucson, Arizona • Encinitas, California • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 14, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

NCT01031680
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypertension, Inadequate Glycaemic Control
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
60
States / cities
Gulf Shores, Alabama • Phoenix, Arizona • Burbank, California + 57 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 14, 2026, 10:20 PM EDT
Completed No phase listed Observational

11C-PIB PET Study in MESA at Columbia University

NCT03981380
View directory record Official record
Conditions
Cognitive Impairment, Vascular Diseases, Alzheimer Disease, Atherosclerosis
Interventions
11C-PIB
Drug
Lead sponsor
José A. Luchsinger
Other
Eligibility
60 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 14, 2026, 10:20 PM EDT